FGFR2 and breast carcinoma: We previously identified that the downregulation of Pleckstrin Homology-Like Domain family A member 1 (PHLDA1) underpins resistance to receptor tyrosine kinase (RTK)-targeted therapy in both fibroblast growth factor receptor 2 (FGFR2)-mutant endometrial and HER2-amplified breast cancers [7].